Video

Dr. Turner on Important Steps for Genomic Profiling in Gynecologic Malignancies

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.

To implement a precision medicine or next-generation sequencing program, Turner says, necessary infrastructure needs to be in place. A pharmacist is needed because physicians will likely be using drugs they’ve never seen before. A dedicated individual is also needed to help interpret the results. A commercial partner will do the best they can, but they don’t normally have the expertise of a clinician in terms of various treatment options. Next, a database is needed to keep track of the rapidly evolving treatment landscape and relevant clinical trials. For example, 2 years ago, a patient with microsatellite instability-high disease didn’t have many treatment options. Now, they can receive immunotherapy.

Turner adds that this shows a lot of promise in non-ovarian malignancies.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD